Alpha Tau Medical Ltd. (DRTS) Form 6-K — Aug 31, 2026
Alpha Tau Medical completed patient enrollment in its IMPACT pilot study of Alpha DaRT in newly diagnosed unresectable pancreatic cancer, treating 48 patients after expanding the study three times from an original target of 12 on strong clinician and patient demand. The multicenter study is running under a U.S. Investigational Device Exemption at 10 clinical centers in the United States, Canada and Israel, delivering Alpha DaRT as a one-time intratumoral add-on to first-line chemotherapy with either mFOLFIRINOX or gemcitabine plus Abraxane.
Key figures
- Clinical Centers
- 10
- Patients Enrolled
- 48
- Data Release Timing
- early 2027
- Max Follow Up Months
- 6
- Clinical Trials Gov Id
- NCT06698458
- Enrollment Expansions
- 3
- Original Enrollment Target
- 12
- Inoperable At Diagnosis Percent
- up to 87%
- Us Pancreatic Cancer Cases Per Year
- approximately 66,000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.